Am­gen sev­ers 14-year Cy­to­ki­net­ics part­ner­ship, bail­ing on ome­cam­tiv af­ter mixed PhI­II re­sults

Am­gen is shrug­ging off a 14-year de­vel­op­ment al­liance and the tens of mil­lions of dol­lars spent to de­vel­op a new heart drug at Cy­to­ki­net­ics af­ter a Phase III tri­al turned up weak da­ta — leav­ing Cy­to­ki­net­ics to sol­dier on alone.

Ome­cam­tiv mecar­bil tech­ni­cal­ly worked, meet­ing the pri­ma­ry com­pos­ite end­point in the Phase III GALAC­TIC-HF study. But it missed a key sec­ondary end­point, which an­a­lysts had been fol­low­ing as a key mark­er for suc­cess — re­duc­tion of car­dio­vas­cu­lar (CV) death. While Cy­to­ki­net­ics cel­e­brat­ed the re­sults, its stock tanked 43% up­on the news, and an­a­lysts warned of an un­cer­tain path ahead. Now, Am­gen wants out.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER